Monopar Therapeutics - 8-K Filing
Monopar Therapeutics announced new analyses from the Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline) showing greater neurologic and global clinical benefit versus standard of care in Wilson disease patients. The results will be presented at the European Academy of Neurology Congress, June 27–30, 2026. These findings support Monopar’s planned New Drug Application submission to the FDA for ALXN1840 in mid-2026. (Items: 7.01 Regulation FD Disclosure On June 26, 2026, Monopar Therapeutics Inc, 9.01 Financial Statements and Exhibits)
Tickers: $MNPR